IP Library Granted Patent US 6,881,831
Granted Patent B2
US 6,881,831 · App. 10/146,175 · Granted Apr 19, 2005

Nucleic acid-based compounds and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,881,831
App. No.
10/146,175
Granted
Apr 19, 2005
Kind
B2
Abstract

The invention provides compounds capable of treating against hepatitis infections, particularly hepatitis B viral infections. Compounds of the invention are nucleic acid-based and preferably comprise 2, 3, 4, 5 or 6 nucleoside units.

Claims (12)

1. A compound having the structure

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound of claim 1 in combination with a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2 wherein the pharmaceutically acceptable carrier comprises a lipid.

4. A pharmaceutical composition for treating viral infections comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier.

5. A pharmaceutical composition for treating HBV infection comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier.

6. A pharmaceutical composition for treating a viral infection comprising a therapeutically effective amount of a compound of claim 1 in combination with a therapeutically effective amount of a reverse transcriptase inhibitor and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition of claim 6 wherein the reverse transcriptase inhibitor is 3TC.

8. A method for treating a subject who is suffering from or susceptible to an HBV infection, comprising administering to the subject an effective amount of a compound having the structure

or a pharmaceutically acceptable salt thereof.

9. The method of claim 8 wherein the subject is suffering from or susceptible to a drug resistant HBV infection.

10. The method of claim 8 wherein the subject is human.

Assignments (4)
CHANGE OF NAME Recorded Feb 2, 2005
From: MICROLOGIX BIOTECH, INC.
To: MIGENIX INC.
Reel/Frame 015646/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 27, 2002
From: IYER, RADHAKRISHNAN P.; JIN, YI; ROLAND, ARLENE
To: ORIGENIX TECHNOLOGIES, INC.
Reel/Frame 013606/0276 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2002
From: ORIGENIX TECHNOLOGIES INC.
To: MICROLOGIX BIOTECH INC.
Reel/Frame 013586/0125 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2002
From: ZHOU, WENQIANG
To: MICROLOGIX BIOTECH INC.
Reel/Frame 013536/0196 →